Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Xingsheng Hu's publication output changed over time?
ScholarIQpublication output · 2014–2023
Output grew0% over the shown period — from 2 works in 2014 to 2 in 2023.
2
1
1
3
1
2
201420172019202020212023
What are the most-cited papers on Xingsheng Hu?
ScholarIQmost cited works
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
Yuankai Shi, Xingsheng Hu, Shucai Zhang, Dongqing Lv, Lin Wu, Qitao Yu, Yiping Zhang, Li Liu, Xiang Wang, Ying Cheng, Zhiyong Ma, Hongrui Niu, Dong Wang, Jifeng Feng, Cheng Huang, Chunling Liu, Hui Zhao, Jingzhang Li, Xiaodong Zhang, Yong Jiang, Chuan Gu
The Lancet Respiratory Medicine. 2021124 Citations
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Yuankai Shi, Shucai Zhang, Xingsheng Hu, Jifeng Feng, Zhiyong Ma, Jianying Zhou, Nong Yang, Lin Wu, Wangjun Liao, Dafang Zhong, Xiaohong Han, Ziping Wang, Xiaodong Zhang, Shukui Qin, Kejing Ying, Jian Feng, Jian Fang, Li Liu, Yong Jiang
Journal of Thoracic Oncology. 2020111 CitationsOPEN ACCESS
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer
Hui Xia, Xingyang Xue, Huaxin Ding, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Xingsheng Hu, Sai‐Hong Ignatius Ou
Clinical Lung Cancer. 201994 Citations
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
Shun Lü, Jianying Zhou, Hong Jian, Lin Wu, Ying Cheng, Yun Fan, Jian Fang, Gongyan Chen, Zhihong Zhang, Dongqing Lv, Liyan Jiang, Rong Wu, Xiangming Jin, Xiaodong Zhang, Junhong Zhang, Conghua Xie, Gengyun Sun, Dongning Huang, Jiuwei Cui, Renhua Guo, Zhigang Han, Zhendong Chen, Jin Liang, Wu Zhuang, Xingsheng Hu, Aimin Zang, Yi Zhang, Shundong Cang, Yuanbo Lan, Xi Chen, Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang Wu
The Lancet Respiratory Medicine. 202372 Citations
Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
Chaoyuan Liu, Wei Zhao, Junpeng Xie, Huashan Lin, Xingsheng Hu, Chang Li, Youlan Shang, Yapeng Wang, Yingjia Jiang, Meng-Ge Ding, Muyun Peng, Tian Xu, Ao’ran Hu, Yuda Huang, Yuan Gao, Xianling Liu, Jun Liu, Fang Ma
Frontiers in Immunology. 202368 CitationsOPEN ACCESS
Related on ScholarIQ
Capital Medical University
Institution
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
Paper
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Paper
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer
Paper
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
Paper
Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
Paper